Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure

Oncology stocks

Ready to invest in the cancer industry? Consider these 9 stocks.

The best oncology stocks depend on your portfolio and investment goals — while volatility can be ideal for day traders, long-term investors will want to look to stocks with steadier gains over time.

9 oncology stocks to watch

We round up a selection of stocks in or related to the cancer industry, weighting the list more heavily towards popular mid- and large-cap US stocks.

  1. Amgen (AMGN)
  2. Bristol-Myers Squibb Company (BMY)
  3. Five Prime Therapeutics (FPRX)
  4. Gilead Sciences (GILD)
  5. Novartis AG ADR (NVS)
  6. Cardiff Oncology (CRDF)
  7. Surface Oncology (SURF)
  8. Trillium Therapeutics (TRIL)
  9. Mersana Therapeutics (MRSN)

Compare trading platforms

Compare online trading platforms by fees, asset types and bonuses to find the best for your investment in oncology stocks.
1 - 8 of 8
Name Product Asset types Signup bonus
SoFi Invest
Stocks, ETFs, Cryptocurrency
$10 - $100
when you open an account and place a first crypto trade of $50 - $5,000+
A free way to invest in most equities.
eToro
Stocks, ETFs, Cryptocurrency
8%-12% of your deposit
when you sign up and deposit at least $50. T&Cs apply.
Trade stocks in the app or online with $0 commissions. Not available in NY, NV, MN, TN, and HI.
Public
Stocks, ETFs, Cryptocurrency
Receive a free stock slice worth between $3–$300
when you sign up for an account and deposit at least $20.
Commission-free trading in stocks and ETFs with a social networking twist.
Tastyworks
Stocks, Options, ETFs, Cryptocurrency
$200 in US stocks
when you open and fund an account with min. $2,000 for 3+ mos.
Trade stocks, options, ETFs and futures on mobile or desktop with this advanced platform.
JPMorgan Self-Directed Investing
Stocks, Bonds, Options, Mutual funds, ETFs
$125 - $625
when you open and fund an account with $25,000 - $250,000+
INVESTMENT AND INSURANCE PRODUCTS ARE: NOT A DEPOSIT • NOT FDIC INSURED • NO BANK GUARANTEE • MAY LOSE VALUE
Robinhood
Stocks, Options, ETFs, Cryptocurrency
Get a free stock
when you successfully sign up and link your bank account.
Make unlimited commission-free trades, plus earn 3% interest on uninvested cash in your account with Robinhood Gold.
Ally Invest Self-Directed Trading
Stocks, Bonds, Options, Mutual funds, ETFs
$100
when you deposit or transfer $10,000–$24,900
500+ commission-free ETFs, some of the industry's lowest fees plus a cash bonus up to $3,000.
Tradier
Stocks, Options, ETFs
N/A
Customize your trade platform or build your own Deep tools, charts and screens Analyzers to help you study before you trade
loading

Compare up to 4 providers

*Signup bonus information updated weekly.

Take a deeper dive into oncology stocks

If you're interested in investing in the cancer industry, take a closer look at what companies in this industry do and how the stocks have historically performed. Keep in mind that positive past performance doesn't guarantee that a stock will continue to rise in the future.

1. Amgen (AMGN)

Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. It focuses on inflammation, oncology/hematology, bone health, cardiovascular disease, nephrology, and neuroscience areas.

Amgen stock opened the day at $226.97 after a previous close of $226.87. The latest price was $225.99 (25-minute delay). Amgen is listed on the NASDAQ, has a trailing 12-month revenue of around USD26.4 billion and employs 24,200 staff.

  • Market capitalization: $123,440,676,864
  • P/E ratio: 19.6224
  • PEG ratio: 1.3142

Back to top


2. Bristol-Myers Squibb Company (BMY)

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, and markets biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, neuroscience, and covid-19 diseases. The company's products include Revlimid, an oral immunomodulatory drug for the treatment of multiple myeloma; Eliquis, an oral inhibitor for reduction in risk of stroke/systemic embolism in NVAF, and for the treatment of DVT/PE; Opdivo for anti-cancer indications; Pomalyst/Imnovid indicated for patients with multiple myeloma; and Orencia for adult patients with active RA and psoriatic arthritis.

Bristol-Myers Squibb Company stock opened the day at $70.74 after a previous close of $70.15. The latest price was $70.36 (25-minute delay). Bristol-Myers Squibb Company is listed on the NYSE, has a trailing 12-month revenue of around USD$47.1 billion and employs 32,200 staff.

  • Market capitalization: $150,984,228,864
  • P/E ratio: 23.4917
  • PEG ratio: 2.4369

Back to top


3. Five Prime Therapeutics (FPRX)

Five Prime Therapeutics, Inc. , a clinical-stage biotechnology company, focuses on the development of immuno-oncology and targeted cancer therapies. The company's product candidates comprise Bemarituzumab, an antibody that inhibits fibroblast growth factor receptor 2b, or FGFR2b to treat patients with gastric or gastroesophageal junction and GEJ cancer; FPT155, a soluble CD80 fusion protein that enhances co-stimulation of T cells through CD28 that is in Phase Ia/1b clinical trial for patients with solid tumors; and BMS-986258, an anti-T cell immunoglobulin and mucin domain-3 antibody, which is in Phase I/II clinical trial in combination with Opdivo in patients with advanced malignant tumors.

Five Prime Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$13.2 million and employs 51 staff.

  • Market capitalization: $1,769,735,936
  • PEG ratio: 0.14

Back to top


4. Gilead Sciences (GILD)

Gilead Sciences, Inc. , a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of coronavirus disease 2019; and Epclusa, Harvoni, Vosevi, Vemlidy, and Viread for the treatment of liver diseases.

Gilead Sciences stock opened the day at $62.43 after a previous close of $62.34. The latest price was $62.63 (25-minute delay). Gilead Sciences is listed on the NASDAQ, has a trailing 12-month revenue of around USD$27.5 billion and employs 14,400 staff.

  • Market capitalization: $78,135,083,008
  • P/E ratio: 19.0642
  • PEG ratio: 0.5358

Back to top


5. Novartis AG ADR (NVS)

Novartis AG researches, develops, manufactures, and markets healthcare products worldwide. The company operates through two segments, Innovative Medicines and Sandoz. The Innovative Medicines segment offers prescription medicines for patients and healthcare providers.

Novartis AG ADR stock opened the day at $75.57 after a previous close of $74.61. The latest price was $74.65 (25-minute delay). Novartis AG ADR is listed on the NYSE, has a trailing 12-month revenue of around USD$52.8 billion and employs 108,000 staff.

  • Market capitalization: $173,483,196,416
  • P/E ratio: 7.7995
  • PEG ratio: 4.3364

Back to top


6. Cardiff Oncology (CRDF)

Cardiff Oncology, Inc. , a clinical-stage oncology company, develops medicine treatment for cancer patients in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor for anti-cancer therapeutics; CY140, an inhibitor of PLK1, PLK2, and PLK3 that is in phase 1/2 studies in solid tumors and leukemias; metastatic colorectal cancer that is in clinical trials; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab.

Cardiff Oncology stock opened the day at $7.78 after a previous close of $7.66. The latest price was $7.87 (25-minute delay). Cardiff Oncology is listed on the NASDAQ, has a trailing 12-month revenue of around USD$384,000 and employs 22 staff.

  • Market capitalization: $68,035,792

Back to top


7. Surface Oncology (SURF)

Surface Oncology, Inc. , a clinical-stage immuno-oncology company, engages in the development of cancer therapies in the United States. The company develops various antibodies that include NZV930, a fully human immunoglobulin isotype G4 monoclonal antibody for the production of extracellular adenosine; SRF617, a fully human IgG4 monoclonal antibody that inhibits CD39 enzymatic activity for the production of adenosine and the breakdown of adenosine triphosphate; SRF388 targeting interleukin 27; GSK4381562, an antibody targeting CD112R, an inhibitory protein expressed on natural killer and T cells; and SRF114 targeting the chemokine receptor CCR8.

Surface Oncology stock opened the day at $7.14 after a previous close of $7.12. The latest price was $7.12 (25-minute delay). Surface Oncology is listed on the NASDAQ, has a trailing 12-month revenue of around USD$30.5 million and employs 67 staff.

  • Market capitalization: $63,837,400

Back to top


8. Trillium Therapeutics (TRIL)

As of November 17, 2021, Trillium Therapeutics Inc. was acquired by Pfizer Inc. Trillium Therapeutics Inc.

Trillium Therapeutics stock opened the day at $8.67 after a previous close of $8.63. The latest price was $8.50 (25-minute delay). Trillium Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$43,000 and employs 33 staff.

  • Market capitalization: $1,936,107,904
  • PEG ratio: 0

Back to top


9. Mersana Therapeutics (MRSN)

Mersana Therapeutics, Inc. , a clinical stage biopharmaceutical company, develops antibody drug conjugates (ADC) for cancer patients with unmet need. It develops XMT-1592, a Dolasynthen ADC targeting NaPi2b-expressing tumor cells, which is in phase I clinical trial for the treatment of ovarian cancer and NSCLC adenocarcinoma.

Mersana Therapeutics stock opened the day at $12.90 after a previous close of $12.85. The latest price was $12.88 (25-minute delay). Mersana Therapeutics is listed on the NASDAQ, has a trailing 12-month revenue of around USD$6.3 million and employs 169 staff.

  • Market capitalization: $597,591,168
  • PEG ratio: 0

Back to top

How to buy oncology stocks

Sign up with an online broker or platform to invest in one or more of these oncology stocks.

  1. Compare share trading platforms. Use our comparison table to narrow down top brokers by fees and bonuses.
  2. Open and fund your brokerage account. You’ll need personal and financial details, like your contact and bank information.
  3. Search for the stock you're interested in. Find the stock by name or ticker symbol, like AMGN or BMY.
  4. Decide on how many to buy. Some brokers will allow you to purchase fractional shares, while others require you to purchase whole shares.
  5. Choose an order type. Invest in the oncology stocks now with a market order or use a limit order to delay your purchase until the stock reaches your desired price.
  6. Buy the stock. Tap or click the Buy button on your brokerage account. Once you’ve invested in the cancer industry, track how your stock performs to decide when it’s time to sell.

The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.

Bottom line

While it’s possible to turn a profit investing in oncology stocks, keep in mind that — like any investment — oncology stocks are not immune to risk. These stocks are subject to fluctuating conditions — both in the market and in the cancer industry, so carefully vet your picks before you invest. And if you’re new to investing, or if it’s been awhile since you’ve taken a critical look at your investing accounts, compare brokers to make sure you’re getting the best features in your trading account.

More guides on Finder

Ask an Expert

You are about to post a question on finder.com:

  • Do not enter personal information (eg. surname, phone number, bank details) as your question will be made public
  • finder.com is a financial comparison and information service, not a bank or product provider
  • We cannot provide you with personal advice or recommendations
  • Your answer might already be waiting – check previous questions below to see if yours has already been asked

Finder.com provides guides and information on a range of products and services. Because our content is not financial advice, we suggest talking with a professional before you make any decision.

By submitting your comment or question, you agree to our Privacy and Cookies Policy and finder.com Terms of Use.

Questions and responses on finder.com are not provided, paid for or otherwise endorsed by any bank or brand. These banks and brands are not responsible for ensuring that comments are answered or accurate.
Go to site